



ITW

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/678,817	
	Filing Date	10/01/2003	
	First Named Inventor	Bobrowski, Paul	
	Art Unit	1654	
	Examiner Name		
Total Number of Pages in This Submission	Attorney Docket Number	PHMC0745-023	Customer No. 26948

<b>ENCLOSURES</b> <i>(check all that apply)</i>		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Non-patent IDS submission(s).
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<b>Remarks</b>	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>	
Firm or Individual name	Ellis & Venable, P.C.
Signature	Michael F. Campillo <span style="float: right;">Reg. No. 44583</span>
Date	June 27, 2005

<b>CERTIFICATE OF TRANSMISSION/MAILING</b>			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.P. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Type or printed	Michael F. Campillo		
Signature	<i>Michael F. Campillo</i>	Date	June 27, 2005



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Application of: Bobrowski, Paul	Art Group: 1654
Serial No.: 10/678,817	Examiner:
Filed: 10/03/2003	Atty. Docket No.: PHMC0745-023
For: Improved oral rehydration methods and compositions	
Customer No. : 26948	

---

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTARY INFORMATION DISCLOSURE STATEMENT**

Sir:

Attached hereto is a supplementary Form PTO-1449 listing documents believed relevant to the subject application. It is respectfully requested that these documents be considered by the examiner and an initialed copy of each form be returned to the undersigned.

By submitting this information disclosure statement, no representation is made that: (i) a search has been performed or the extent of any search that may have been performed; (ii) more relevant information does not exist; (iii) the information is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b); (iv) the information is prior art or otherwise relevant to the patentability of the claimed invention; (v) the order of presentation of the information is an indication of the importance of the information; or (vi) if this is an e-IDS, any gap in the numbering of the information is an indication that information was deleted.

It is believed that this disclosure complies with the requirements of 37 C.F.R. §§ 1.56, 1.97, and 1.98, and the Manual of Patent Examining Procedures § 609. If

for some reason the examiner considers otherwise, it is respectfully requested that the undersigned be called so that any deficiencies can be remedied.

A copy of each document is enclosed. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

These documents are not necessarily analogous art.

The relevance of each document will now be discussed.

Document Sheng Y, Pero RW, Wagner H. Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from Uncaria tomentosa. Phytomedicine. 2000;7(2):137-143. This reference was cited in a Request for Reexamination sought for U.S. Pat. No. 6,797,286. The subject application is related in subject matter to the '286 patent. The Third Party alleges that this reference teaches a Uncaria tomentosa extract having depleted oxindole alkaloids.

Respectfully submitted,

Ellis & Venable

Date: June 27, 2005

By: Michael F. Campillo  
Michael F. Campillo, Reg. No. 44583

Attorneys for Applicant  
101 North First Avenue, Suite 1875  
Phoenix, Arizona 85003-1910  
(602) 631-9100

Attachments: Form PTO-1449



# CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage paid, in an envelope addressed to:

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on 6-27-05

By: Michael L. Cuth



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/678,817
Filing Date	10/03/2003
First Named Inventor	Bobrowski, Paul J.
Art Unit	1654
Examiner Name	
Attorney Docket Number	PHMC0745-023

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Sheng Y, Pero RW, Wagner H. Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from Uncaria tomentosa. Phytomedicine. 2000;7(2):137-143.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.